Antibody-drug conjugates, widely known as ADCs, are a class of cancer therapy that works like a guided missile: a lab-made antibody steers a potent cell-killing chemical directly to tumor cells, sparing most healthy tissue along the way. The concept fuses the precision of immunotherapy with the raw destructive power of chemotherapy, and after decades of refinement, ADCs have become one of the fastest-growing segments of oncology drug development.1PubMed Central. Antibody-Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives The technology sounds simple in outline, but making it actually work inside a human body has required solving an extraordinary number of engineering problems, from choosing the right molecular target to keeping the drug attached until it reaches the right cell.
How an ADC Is Built
Every ADC has three parts. The antibody is the guidance system. It recognizes a specific protein, called an antigen, that sits on the surface of cancer cells. The payload is the weapon, a small-molecule drug so toxic that it would cause unacceptable harm if injected on its own. And the linker is the chemical tether holding the payload to the antibody, engineered to stay intact in the bloodstream yet break apart once the ADC reaches the inside of a tumor cell.2PubMed Central. Antibody-Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives Each of these three components presents its own set of trade-offs, and changing any one of them can dramatically alter how the drug behaves.
The antibody component is typically a monoclonal antibody, a large protein engineered to latch onto one specific antigen with high affinity. Because antibodies also interact with the immune system and have their own pharmacokinetic behavior, researchers can tweak features like how long the antibody circulates in the blood, how readily it triggers immune responses, and how efficiently it gets pulled inside a cell once it binds its target.3PubMed Central. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective These tweaks make the difference between an ADC that works in theory and one that actually shrinks tumors in patients.
Choosing the Right Target
An ADC is only as good as the address it is mailed to. The ideal target antigen is heavily expressed on the surface of tumor cells but mostly absent from healthy tissues. When the antigen is too common on normal cells, the drug ends up killing those cells too, producing toxicity that defeats the purpose of targeted delivery. Beyond expression level, developers also consider whether the antigen is reliably present across different patients with the same cancer type, whether tumors tend to shed or downregulate the antigen over time, and whether binding the antigen efficiently triggers the cell to pull the whole ADC complex inside.4PubMed Central. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
HER2, the target of some of the best-known ADCs, illustrates the importance of expression levels. Data now suggest that the density of HER2 protein on a patient’s tumor cells strongly influences how well HER2-targeted ADCs work. Higher receptor density means more ADC molecules get pulled into the cell, amplifying the drug’s effect. Immunohistochemistry scoring, which rates expression from 0 to 3+, has emerged as the primary method for choosing which patients are likely to benefit.5PubMed. Companion diagnostics and HER2-targeted antibody-drug conjugates This kind of companion diagnostic testing is becoming standard before prescribing ADCs, because giving the drug to a patient whose tumor expresses little or none of the target antigen wastes time and exposes them to side effects for minimal gain.
What Happens After Binding
Once an ADC locks onto its antigen, the cell pulls the complex inward through a process called endocytosis. Several uptake routes exist, but the cell most commonly engulfs the ADC into small membrane-bound compartments that eventually fuse with lysosomes, the cell’s recycling centers.6PubMed Central. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates Inside the lysosome, enzymes or acidic conditions break the linker, releasing the toxic payload. The freed drug then travels to its intracellular target and kills the cell. How efficiently this chain of events proceeds determines the ADC’s potency, so the entire intracellular journey matters as much as the initial binding event.7PubMed Central. Fate of Antibody-Drug Conjugates in Cancer Cells
The Bystander Effect
Solid tumors are not uniform. Even within a single mass, some cells may express the target antigen heavily while neighboring cells express little or none. This heterogeneity is a significant challenge, because an ADC that only kills antigen-positive cells will leave pockets of resistant tumor behind. Some ADCs get around this through the bystander killing effect: after the payload is released inside an antigen-positive cell, the drug diffuses out and kills nearby antigen-negative cells as well.8PubMed. Bystander effect of antibody-drug conjugates: fact or fiction?
Whether an ADC can produce a bystander effect depends largely on the payload’s chemical properties and the type of linker. Payloads that are more hydrophobic cross cell membranes more easily, and cleavable linkers release the drug in a form that can escape the first cell. Developers are actively engineering payloads optimized for this characteristic, aiming to improve potency against heterogeneous tumors while also reducing susceptibility to drug resistance.9PubMed. PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux The bystander effect remains somewhat controversial, though. Its strength varies by tumor type, local tissue architecture, and the specific ADC design, making it difficult to predict reliably in every patient.
Payloads and Why They Differ
The drugs carried by ADCs are far more toxic than standard chemotherapy agents. They have to be, because only a small fraction of the injected dose actually reaches the tumor. Two of the most established payload families are maytansinoids and auristatins. Both interfere with tubulin, a structural protein that cells need to divide, but they bind slightly different sites on the tubulin molecule. Maytansinoids attach to the maytansine binding site, while auristatins bind the vinca alkaloid site; in both cases, the result is that cancer cells cannot complete cell division and die.10PubMed Central. Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
A newer wave of payloads targets a completely different mechanism. Topoisomerase I inhibitors interfere with enzymes that manage the coiling and uncoiling of DNA during replication. Several ADCs now in clinical use or in trials carry camptothecin-derived payloads that block topoisomerase I, and they have shown activity in cancers that respond poorly to tubulin-targeting ADCs.11PubMed Central. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates The diversification of payload classes matters because tumors that develop resistance to one type of cell-killing mechanism may still be vulnerable to another.
How Linker Design Shapes Safety
The linker does not get much public attention, but it profoundly affects both how well an ADC works and how sick it makes the patient. Linkers fall into two broad categories: cleavable, meaning they are designed to break under specific conditions inside tumor cells, and non-cleavable, meaning the entire antibody-linker-payload complex must be degraded inside the lysosome to free the drug.
A large meta-analysis comparing the two types found that ADCs with cleavable linkers produced higher rates of serious side effects. Roughly 47% of patients treated with cleavable-linker ADCs experienced grade 3 or higher adverse events, compared with about 34% for non-cleavable linkers. The difference was driven partly by higher rates of neutropenia and anemia in the cleavable group.12PubMed Central. Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis The reason is intuitive: a linker that breaks easily inside tumor cells can also break prematurely in the bloodstream, releasing the toxic payload before it reaches its destination. Non-cleavable linkers are more stable, but they sacrifice some of the bystander killing effect because the freed drug is typically trapped in a form that does not easily diffuse to neighboring cells. Designers have to weigh these trade-offs for every new ADC program.
Site-Specific Conjugation and the Drug-to-Antibody Ratio
Early ADCs were made by attaching payloads to whatever reactive amino acid residues were available on the antibody surface, most commonly lysines. The problem with this approach is randomness: each antibody molecule might end up carrying a different number of payload molecules at different positions, producing a heterogeneous mixture that is harder to characterize, harder to manufacture consistently, and harder to dose reliably.13PubMed Central. Bioprocess development of antibody-drug conjugate production for cancer treatment
The field has increasingly moved toward site-specific conjugation, in which engineered sites on the antibody are used as defined attachment points for the payload. Two ADCs made using conjugation to engineered cysteine residues have already won regulatory approval, lending credibility to the approach.14PubMed. An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio A more uniform product means every molecule in the vial behaves similarly in the patient, which should translate into more predictable safety and efficacy. The drug-to-antibody ratio, or DAR, measures how many payload molecules each antibody carries. Too few and the drug is not potent enough; too many and the antibody becomes unstable or gets cleared from the blood too quickly. Most modern ADCs aim for a DAR between two and eight.
How Tumors Resist ADCs
As with nearly every cancer therapy, tumors find ways to evade ADCs. The resistance mechanisms fall into a few broad categories. The most straightforward is downregulation of the target antigen: cancer cells simply make less of the surface protein the ADC is designed to bind. In laboratory studies of brentuximab vedotin resistance, for example, resistant lymphoma cell lines showed reduced CD30 expression compared with their parent cells.15Cancer Biology & Medicine. Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives
A second route involves drug efflux pumps. Some cancer cells, especially those in tumors that have already been treated with multiple rounds of chemotherapy, ramp up production of proteins called ABC transporters. These molecular pumps sit in the cell membrane and actively eject cytotoxic drugs before they can do their damage. Payloads derived from natural products, including both maytansinoids and auristatins, are known substrates for these pumps.16Cancer Biology & Medicine. Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives A third category involves problems with intracellular processing, where the cell fails to break down the ADC and release the payload efficiently, or the payload’s intracellular target itself mutates.17PubMed Central. Mechanisms of Resistance to Antibody-Drug Conjugates
Understanding these escape routes has become essential for designing the next wave of ADCs. Newer payloads are being engineered specifically to resist efflux pump activity, and dual-payload strategies aim to overwhelm the cell’s ability to develop resistance to any single mechanism.
Safety Concerns Beyond the Usual Side Effects
Most ADC side effects are predictable extensions of what the payload does to healthy cells that divide quickly: low blood counts, fatigue, nausea. But one toxicity has generated particular concern. Interstitial lung disease, a potentially life-threatening inflammatory condition affecting the lungs, has been associated with several different ADCs. The mechanism appears to involve an unintended pathway: alveolar macrophages, the immune cells that patrol the lungs, take up ADCs through receptors on their surface that recognize the antibody’s constant region, not the target antigen. After internalizing the ADC, these macrophages release the payload internally, triggering inflammation and lung injury in a dose-dependent fashion.18PubMed. Interstitial lung disease in patients treated with antibody-drug conjugates: a review This is an off-target effect that has nothing to do with the tumor at all, and it illustrates why even a “targeted” therapy still has systemic risks that require close monitoring.
Combining ADCs With Other Treatments
One of the most active research areas is pairing ADCs with other types of cancer therapy. The rationale is that ADCs kill tumor cells through one mechanism, and a second agent can attack a different vulnerability or boost the immune system’s response to the dying tumor. Combinations under study include ADCs paired with immune checkpoint inhibitors, standard chemotherapy, small-molecule inhibitors that block cancer growth signals, and even CAR-T cell therapy. Clinical trials of these combinations have shown improved response rates and longer progression-free survival across several cancer types compared with ADCs alone.19PubMed Central. Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
The pairing with checkpoint inhibitors is particularly interesting. When an ADC kills tumor cells, it can release tumor-specific proteins that prime the immune system to recognize the cancer. A checkpoint inhibitor, which removes the brakes that tumors put on immune cells, can then amplify that immune response. In theory, the two treatments create a feedback loop: the ADC exposes the tumor to the immune system, and the checkpoint inhibitor makes sure the immune system follows through.
Dual-Payload and Bispecific ADCs
A major limitation of traditional ADCs is that they carry only one type of drug and target only one antigen. If the tumor is heterogeneous, with some cells expressing the target and some not, or if the cells develop resistance to the payload, the ADC can lose effectiveness. Two engineering strategies aim to address this. Dual-payload ADCs carry two different cytotoxic drugs on a single antibody, enabling the simultaneous delivery of drugs that kill cells through different mechanisms. The idea is that a cell resistant to one payload may still be vulnerable to the other.20PubMed Central. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
Bispecific ADCs take a different tack by engineering the antibody itself to recognize two different antigens. One preclinical candidate targets both EGFR and HER3, two growth factor receptors that are commonly found on the same tumor but regulated independently.21Cancer Research. JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities By binding two targets at once, the ADC can stick to tumor cells even if one target is downregulated and can deliver its payload to a broader set of cancer cells within a heterogeneous tumor. Both approaches are still largely in early-stage development, but they represent the clearest attempt to overcome the limitations that hold back current ADCs.
Measuring ADC Behavior in Patients
Characterizing how an ADC moves through the body is more complicated than tracking a typical drug. Unlike a simple pill that dissolves into one measurable compound, an ADC is a large molecule that partially degrades over time, shedding payload at varying rates. Researchers must measure several different species in the blood: the intact ADC, the naked antibody that has lost its payload, and the free drug circulating on its own.22PubMed Central. Clinical Pharmacology of Antibody-Drug Conjugates The balance among these species tells clinicians how quickly the linker is breaking down, how much active drug is reaching the tumor versus floating around systemically, and whether dosing adjustments are needed.
Imaging ADCs in Real Time
A newer frontier involves using molecular imaging to track where ADCs actually go in a living patient. By labeling the antibody with a positron-emitting isotope like zirconium-89, researchers can use PET scans to visualize ADC distribution across the whole body. This technique, called immuno-PET, can reveal whether the drug is reaching the tumor, how much is accumulating in off-target organs, and whether target antigen expression is changing over the course of treatment.23PubMed Central. Application of Immuno-PET in Antibody-Drug Conjugate Development
In a proof-of-concept study, researchers created a dual-labeled construct carrying both the payload MMAE and zirconium-89 on the same trastuzumab antibody. The construct enabled clear PET visualization of HER2-positive tumors in mice, with tumoral uptake reaching about 70% of the injected dose per gram of tissue, while simultaneously delivering a therapeutic payload.24PubMed Central. Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET In separate imaging work, immuno-PET detected changes in tumor HER2 expression during ADC treatment, showing that the technique could serve as a real-time readout of whether the drug is working and how the tumor is responding.25Journal of Nuclear Medicine. Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins If immuno-PET matures into clinical practice, it could allow oncologists to see, rather than guess, whether a given patient’s tumor is actually taking up the ADC they have been prescribed.
Moving Beyond Cancer
ADC technology was developed for oncology, and all currently approved ADCs carry cancer indications. But the underlying principle, delivering a potent drug only to cells that display a specific marker, applies to other diseases as well. Researchers are now exploring ADCs for autoimmune conditions, chronic inflammatory diseases, and infections.26PubMed. Antibody-drug conjugates: From oncological milestones to emerging non-oncological applications In autoimmune diseases, for instance, the goal would be to selectively destroy the immune cells that are attacking the patient’s own tissues, sparing the rest of the immune system. In inflammatory bowel disease, arthritis, and chronic kidney inflammation, conjugates could target cells bearing markers that are upregulated in inflamed tissue, releasing anti-inflammatory or immunosuppressive drugs right at the site of damage.27Advanced NanoBiomed Research. Peptide/Antibody–Drug Conjugates for Therapeutic Applications in Inflammatory Disease None of these non-oncology applications have reached approval yet, but they represent a substantial expansion of the platform’s ambition. The manufacturing, safety-monitoring, and linker-engineering lessons learned from two decades of cancer-focused ADC development now form the foundation that these newer programs are building on.